Ramipril Capsule
Product Images NDC 72789-415

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Ramipril (NDC 72789-415). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

72789415 Label (72789415)

Packaging label for Ramipril USP 2.5 mg capsules by PD-Rx Pharmaceuticals, Inc., containing 90 capsules. The label includes dosage warning to keep out of reach of children, prescribing information placeholders, reorder number, lot number F24D20, expiration date 01/2025, and the NDC 72789-415-90. The label also features a barcode and QR code for product identification.*

FDA Label Image

Structured Product Formula For Ramipril (F36e6ac7 0cfb 4450 A2f2 84064a9c7d3a 01)

Chemical structure of Ramipril displayed as a molecular diagram showing its atomic bonds and groups. The structure details the arrangement of carbon, hydrogen, nitrogen, and oxygen atoms characteristic of the Ramipril molecule.*

FDA Label Image

Figure 1 (F36e6ac7 0cfb 4450 A2f2 84064a9c7d3a 02)

Kaplan-Meier estimate graph showing the composite outcome proportions of myocardial infarction, stroke, or death from cardiovascular causes over days of follow-up for Ramipril and placebo groups. The chart compares patient proportions between the two groups over approximately 1600 days, with Ramipril represented by a solid line and placebo by a dashed line.*

FDA Label Image

Figure 2 (F36e6ac7 0cfb 4450 A2f2 84064a9c7d3a 03)

A figure titled 'The Beneficial Effect of Treatment with Ramipril on the Composite Outcome of Myocardial Infarction, Stroke, or Death from Cardiovascular Causes Overall and in Various Subgroups.' It presents a forest plot showing relative risk in the Ramipril group versus placebo for different patient subgroups such as cardiovascular disease presence, diabetes, age, sex, hypertension status, history of coronary artery disease, prior myocardial infarction, cerebrovascular disease, peripheral vascular disease, and microalbuminuria. The x-axis measures relative risk ranging approximately from 0.6 to 1.2 with 95% confidence intervals indicated for each subgroup.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.